ETHYL 3-(4-BROMO-2-FLUORO-3-METHOXYPHENYL)-3-OXOPROPANOATE, 95.0%, 100mg

2-(3-Fluoro-4-methoxyphenyl)acetamide, 95%, 500mg

Linsitinib, 2mg

(S)-Methyl 3-(1-amino-2-hydroxyethyl)benzoate hydrochloride, 97.0%, 100mg

tert-butyl (2S)-2-{4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylate, 95%, 1g

6-Bromo-5-methyl-1H-imidazo[4,5-b]pyridine, 95.0%, 250mg

6-chloro-2-methoxy-7-methyl-9-propylimidazo[1,5-a]pyrido[3,2-e]pyrazine, 95.0%, 250mg

1-(BROMOMETHYL)CYCLOPENTENE, 95.0%, 250mg

(Pyridin-3-yloxy)-acetic acid trifluoroacetic acid salt, 95.0%, 1g

Sulfato de cobre(II) pentahidratado, mínimo 98 %, cristalizado, 2,5 kg, envase de plástico.

Gel de sílice amarillo/azul, 2,5-6 mm, con indicador, partido, 10 kg, envase de plástico.

2,6-Difluoro-3-nitropyridine, 95.0%, 10g

Methyl (1S,3R)-3-(tert-butoxycarbonylamino)-2,2-dimethyl-cyclobutanecarboxylate, 98%, 250mg